Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Rhea-AI Summary

Insmed (Nasdaq: INSM) granted inducement equity awards to 103 new employees under its 2025 Inducement Plan, intended to comply with Nasdaq Listing Rule 5635(c)(4).

On May 29, 2026, employees received 97,091 RSUs and options on 12,850 shares at an exercise price of $106.91, with four-year vesting schedules.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Positive

• Inducement awards granted to 103 new employees, supporting talent recruitment and retention
• Equity package includes 97,091 restricted stock units plus options for 12,850 shares
• Options exercise price set at $106.91, matching the Nasdaq closing price on grant date
• Four-year vesting schedules may help align employee incentives with longer-term shareholder interests

Negative

• Equity awards totaling up to 109,941 shares may create future shareholder dilution
• Four-year vesting of RSUs and options implies ongoing non-cash compensation expense over several years

News Market Reaction – INSM

+1.02%

+1.02% News Effect

On the day this news was published, INSM gained 1.02%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement details routine inducement equity awards—97,091 restricted stock units and options...

Analysis

This announcement details routine inducement equity awards—97,091 restricted stock units and options for 12,850 shares at an exercise price of $106.91—granted to 103 new employees under Nasdaq Listing Rule 5635(c)(4). The grants vest over four years and are part of ongoing talent recruitment. In recent months, larger stock moves have been tied to earnings and clinical data, so investors may focus on upcoming fundamental updates and any use of the effective Form S-3ASR shelf when assessing future developments.

Key Figures

Current price: $103.86 New employees: 103 Restricted stock units: 97,091 units +5 more

8 metrics

Current price $103.86 Before publication on 2026-06-04

New employees 103 Employees receiving inducement awards

Restricted stock units 97,091 units Granted on May 29, 2026 under 2025 Inducement Plan

Stock options granted 12,850 shares Options to purchase INSM common stock

Option exercise price $106.91 per share Closing price on Nasdaq Global Select Market on grant date

RSU vesting period 4 years 25% vests on each anniversary schedule

Option term 10 years Term of inducement stock options

Initial vesting tranche 25% Of shares vest on first anniversary reference date

Historical Context

5 past events · Latest: May 27 (Neutral)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
May 27	Conference presentation	Neutral	-2.3%	Announcement of Goldman Sachs healthcare conference presentation and webcast access.
May 07	Earnings update	Positive	-23.4%	Q1 2026 results with strong BRINSUPRI and ARIKAYCE growth and guidance.
May 06	Awareness campaign	Positive	-23.4%	Launch of Suspect Bronchiectasis educational initiative with Ty Pennington.
May 04	Data presentation	Positive	+5.1%	Plans to present six ATS 2026 abstracts including Phase 3b ENCORE results.
Apr 30	Investor conferences	Neutral	+1.0%	Scheduling of BofA and RBC healthcare conference presentations with webcasts.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent history shows larger moves on fundamental or data-heavy updates (earnings, portfolio data) and relatively modest reactions to conference or corporate communications, with a mix of aligned and divergent price responses.

Recent Company History

Over the last months, INSM has reported several milestones. A Q1 2026 earnings and business update detailed $306.0M in revenue and multiple clinical and regulatory developments, yet shares fell 23.41%. Data presentations at ATS 2026 on ARIKAYCE and the respiratory portfolio coincided with a 5.07% gain. In contrast, announcements about investor conferences and a Goldman Sachs presentation produced smaller moves (between about -2% and +1%). Today’s inducement grants fit the pattern of lower-impact corporate news items.

Key Terms

nasdaq listing rule 5635(c)(4), inducement awards, restricted stock units, exercise price, +3 more

7 terms

nasdaq listing rule 5635(c)(4) regulatory

"intended to meet the requirements of a plan providing for inducement grants under Nasdaq Listing Rule 5635(c)(4)"

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

inducement awards financial

"today announced the granting of inducement awards to 103 new employees"

Inducement awards are special bonuses given to new employees to encourage them to join a company, often in the form of stock or money. They matter because they can motivate talented people to choose one company over another and help align their success with the company's growth. Think of it like a signing bonus to seal the deal.

restricted stock units financial

"the employees received 97,091 restricted stock units and options"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

exercise price financial

"options to purchase an aggregate 12,850 shares ... at an exercise price of $106.91 per share"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting schedule financial

"The restricted stock units have a four-year vesting schedule, with 25% of the shares"

A vesting schedule is a timeline that determines when someone gains full ownership of certain benefits, such as company stock or retirement contributions. Think of it like earning the right to own a gift gradually over time, rather than receiving it all at once. It matters to investors because it affects when they can fully access or sell these benefits, influencing their financial planning and decision-making.

nasdaq global select market regulatory

"the closing trading price on the Nasdaq Global Select Market on the date of grant"

A Nasdaq Global Select Market listing is the highest tier of stocks on the Nasdaq exchange, reserved for companies that meet the strictest financial, reporting and governance standards. For investors, it acts like a premium quality label—signaling larger, more transparent and better-governed companies that tend to offer greater liquidity and lower perceived risk compared with lower-tier listings, making it easier to buy, sell and evaluate shares.

stock options financial

"The options have a 10-year term and a four-year vesting schedule"

Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

BRIDGEWATER, N.J., June 4, 2026 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced the granting of inducement awards to 103 new employees. The awards were granted under the Insmed Incorporated 2025 Inducement Plan, which is intended to meet the requirements of a plan providing for inducement grants under Nasdaq Listing Rule 5635(c)(4). The awards were approved by Insmed's Compensation Committee and made as a material inducement to each employee's entry into employment with the Company.

In connection with the commencement of their employment, on May 29, 2026, the employees received 97,091 restricted stock units and options to purchase an aggregate 12,850 shares of Insmed common stock at an exercise price of $106.91 per share, the closing trading price on the Nasdaq Global Select Market on the date of grant.

The restricted stock units have a four-year vesting schedule, with 25% of the shares underlying each restricted stock unit grant vesting on each anniversary of the first day of the month immediately following the grant date, subject to the relevant employee's continued service with Insmed on the applicable vesting date.

The options have a 10-year term and a four-year vesting schedule, with 25% of the shares subject to the option vesting on the first anniversary of the first day of the month immediately following the grant date and 12.5% of the shares subject to the option vesting every six months thereafter through the fourth anniversary thereof, subject to the relevant employee's continued service with Insmed on the applicable vesting date.

About Insmed

Insmed Incorporated is a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases. The Company is advancing a diverse portfolio of approved and mid- to late-stage investigational medicines as well as cutting-edge drug discovery focused on serving patient communities where the need is greatest. Insmed's most advanced programs are in pulmonary and inflammatory conditions, including two approved therapies to treat chronic, debilitating lung diseases. The Company's early-stage programs encompass a wide range of technologies and modalities, including gene therapy, AI-driven protein engineering, RNA end-joining, and synthetic rescue.

Headquartered in Bridgewater, New Jersey, Insmed has offices and research locations throughout the United States, Europe, and Japan. Insmed is proud to be recognized as one of the best employers in the biopharmaceutical industry, including spending five consecutive years as the No. 1 Science Top Employer. Visit www.insmed.com to learn more or follow us on LinkedIn, Instagram, YouTube, and X.

Contact:

Investors:

Bryan Dunn
Vice President, Investor Relations
(646) 812-4030
investor.relations@insmed.com

Media:

Claire Mulhearn
Vice President, Corporate Communications
(862) 842-6819
media@insmed.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/insmed-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-302790346.html

SOURCE Insmed Incorporated

FAQ

What inducement equity grants did Insmed (NASDAQ: INSM) announce on June 4, 2026?

Insmed announced inducement equity awards for 103 new employees, including restricted stock units and stock options. According to Insmed, the grants were issued under its 2025 Inducement Plan as material inducements to employment, consistent with Nasdaq Listing Rule 5635(c)(4) requirements.

How many Insmed (INSM) shares are covered by the June 2026 inducement grants?

The June 2026 inducement grants cover 97,091 restricted stock units and options for 12,850 shares. According to Insmed, these equity awards were granted on May 29, 2026, as part of compensation packages for 103 newly hired employees.

What is the exercise price and term for the new Insmed (INSM) stock options?

The new Insmed stock options have a $106.91 exercise price and a 10-year term. According to Insmed, the options vest over four years, beginning one year after the month following the grant date, subject to continued employee service.

How do the Insmed (INSM) June 2026 inducement RSUs vest for employees?

The Insmed inducement RSUs vest over four years in equal annual installments of 25%. According to Insmed, vesting occurs on each anniversary of the first day of the month following the grant date, contingent on the employee’s continued service.

Why did Insmed (INSM) use Nasdaq Listing Rule 5635(c)(4) for these grants?

Insmed used its 2025 Inducement Plan to make grants intended to qualify under Nasdaq Listing Rule 5635(c)(4). According to Insmed, this rule allows equity awards as material inducements for new employees without prior shareholder approval, within specific conditions.